{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,9,11]],"date-time":"2024-09-11T08:58:35Z","timestamp":1726045115067},"publisher-location":"Cham","reference-count":45,"publisher":"Springer International Publishing","isbn-type":[{"type":"print","value":"9783030316341"},{"type":"electronic","value":"9783030316358"}],"license":[{"start":{"date-parts":[[2019,9,25]],"date-time":"2019-09-25T00:00:00Z","timestamp":1569369600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020]]},"DOI":"10.1007\/978-3-030-31635-8_156","type":"book-chapter","created":{"date-parts":[[2019,9,24]],"date-time":"2019-09-24T17:05:22Z","timestamp":1569344722000},"page":"1276-1282","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Dose-Response to Different Radiochemotherapy Regimens in Locally Advanced Pancreatic Cancer"],"prefix":"10.1007","author":[{"given":"Br\u00edgida C.","family":"Ferreira","sequence":"first","affiliation":[]},{"given":"Joana","family":"Dias","sequence":"additional","affiliation":[]},{"given":"Adriana","family":"Gomes","sequence":"additional","affiliation":[]},{"given":"Panayiotis","family":"Mavroidis","sequence":"additional","affiliation":[]},{"given":"Humberto","family":"Rocha","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2019,9,25]]},"reference":[{"issue":"6","key":"156_CR1","doi-asserted-by":"publisher","first-page":"996","DOI":"10.21037\/jgo.2018.05.15","volume":"9","author":"A Torgeson","year":"2018","unstructured":"Torgeson, A., Tao, R., Garrido-Laguna, I., et al.: Large database utilization in health outcomes research in pancreatic cancer: an update. J. Gastrointest. Oncol. 9(6), 996\u20131004 (2018)","journal-title":"J. Gastrointest. Oncol."},{"issue":"2","key":"156_CR2","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/S0360-3016(99)00197-2","volume":"45","author":"BJ Fisher","year":"1999","unstructured":"Fisher, B.J., Perera, F.E., Kocha, W., et al.: Analysis of the clinical benefit of 5-fluorouracil and radiation treatment in locally advanced pancreatic cancer. Int. J. Radiat. Oncol. Biol. Phys. 45(2), 291\u2013295 (1999)","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"3","key":"156_CR3","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1016\/S0360-3016(01)01708-4","volume":"51","author":"G Boz","year":"2001","unstructured":"Boz, G., Paoli, A., Innocente, R., et al.: Radiotherapy and continuous infusion 5-fluorouracil in patients with nonresectable pancreatic carcinoma. Int. J. Rad. Oncol. Biol. Phys. 51(3), 736\u2013740 (2001)","journal-title":"Int. J. Rad. Oncol. Biol. Phys."},{"issue":"6","key":"156_CR4","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1177\/030089160108700609","volume":"87","author":"MF Osti","year":"2001","unstructured":"Osti, M.F., Costa, A.M., Bianciardi, F., et al.: Concomitant radiotherapy with protracted 5-fluorouracil infusion in locally advanced carcinoma of the pancreas: a phase II study. Tumori 87(6), 398\u2013401 (2001)","journal-title":"Tumori"},{"issue":"2","key":"156_CR5","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1007\/s00066-003-1043-y","volume":"179","author":"AG Morganti","year":"2003","unstructured":"Morganti, A.G., Forni, F., Macchia, G., et al.: Chemoradiation of unresectable pancreatic carcinoma: impact of pretreatment hemoglobin level on patterns of failure. Strahlenther. Onkol. 179(2), 87\u201392 (2003)","journal-title":"Strahlenther. Onkol."},{"issue":"5","key":"156_CR6","doi-asserted-by":"publisher","first-page":"1454","DOI":"10.1016\/j.ijrobp.2004.01.035","volume":"59","author":"A Morganti","year":"2004","unstructured":"Morganti, A., Valentini, V., Macchia, G., et al.: 5-fluorouracil\u2013based chemoradiation in unresectable pancreatic carcinoma: phase I-II dose-escalation study. Int. J. Radiat. Oncol. Biol. Phys. 59(5), 1454\u20131460 (2004)","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"8","key":"156_CR7","doi-asserted-by":"publisher","first-page":"1516","DOI":"10.1002\/(SICI)1097-0142(19970415)79:8<1516::AID-CNCR11>3.0.CO;2-0","volume":"79","author":"H Ishii","year":"1997","unstructured":"Ishii, H., Okada, S., Tokuuye, K., et al.: Protracted 5-fluorouracil infusion with concurrent radiotherapy as a treatment for locally advanced pancreatic carcinoma. Cancer 79(8), 1516\u20131520 (1997)","journal-title":"Cancer"},{"issue":"1","key":"156_CR8","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/S0360-3016(01)02806-1","volume":"53","author":"H Shinchi","year":"2002","unstructured":"Shinchi, H., Takao, S., Noma, H., et al.: Length and quality of survival after external-beam radiotherapy with concurrent continuous 5-fluorouracil infusion for locally unresectable pancreatic cancer. Int. J. Radiat. Oncol. Biol. Phys. 53(1), 146\u2013150 (2002)","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"1","key":"156_CR9","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/S0360-3016(03)00435-8","volume":"57","author":"CP Li","year":"2003","unstructured":"Li, C.P., Chao, Y., Chi, K.H., et al.: Concurrent chemoradiotherapy treatment of locally advanced pancreatic cancer: gemcitabine versus 5-fluorouracil, a randomized controlled study. Int. J. Radiat. Oncol. Biol. Phys. 57(1), 98\u2013104 (2003)","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"3\u20134","key":"156_CR10","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1159\/000081320","volume":"67","author":"H Ueno","year":"2004","unstructured":"Ueno, H., Okusaka, T., Ikeda, M., et al.: Phase I study of hyperfractionated radiation therapy with protracted 5-fluorouracil infusion in patients with locally advanced pancreatic cancer. Oncology 67(3\u20134), 215\u2013221 (2004)","journal-title":"Oncology"},{"issue":"11","key":"156_CR11","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1038\/sj.bjc.6605420","volume":"101","author":"R Wilkowski","year":"2009","unstructured":"Wilkowski, R., Boeck, S., Ostermaier, S., et al.: Chemoradiotherapy with concurrent gemcitabine and cisplatin with or without sequential chemotherapy with gemcitabine\/cisplatin vs chemoradiotherapy with concurrent 5-fluorouracil in patients with locally advanced pancreatic cancer-a multi-centre randomised phase II study. Br. J. Cancer 101(11), 1853\u20131859 (2009)","journal-title":"Br. J. Cancer"},{"issue":"5","key":"156_CR12","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1016\/S0360-3016(01)01580-2","volume":"50","author":"JM Pipas","year":"2001","unstructured":"Pipas, J.M., Mitchell, S.E., Barth Jr., R.J., et al.: Phase I study of twice-weekly gemcitabine and concomitant external-beam radiotherapy in patients with adenocarcinoma of the pancreas. Int. J. Radiat. Oncol. Biol. Phys. 50(5), 1317\u20131322 (2001)","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"8","key":"156_CR13","first-page":"2246","volume":"7","author":"RA Wolff","year":"2001","unstructured":"Wolff, R.A., Evans, D.B., Gravel, D.M., et al.: Phase I trial of gemcitabine combined with radiation for the treatment of locally advanced pancreatic adenocarcinoma. Clin. Cancer Res. 7(8), 2246\u20132253 (2001)","journal-title":"Clin. Cancer Res."},{"issue":"9","key":"156_CR14","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1016\/S0959-8049(02)00076-X","volume":"38","author":"SM Lange","year":"2002","unstructured":"Lange, S.M., van Groeningen, C.J., Meijer, O.W., et al.: Gemcitabine-radiotherapy in patients with locally advanced pancreatic cancer. Eur. J. Cancer 38(9), 1212\u20131217 (2002)","journal-title":"Eur. J. Cancer"},{"issue":"4","key":"156_CR15","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1038\/sj.bjc.6602001","volume":"91","author":"T Okusaka","year":"2004","unstructured":"Okusaka, T., Ito, Y., Ueno, H., et al.: Phase II study of radiotherapy combined with gemcitabine for locally advanced pancreatic cancer. Br. J. Cancer 91(4), 673\u2013677 (2004)","journal-title":"Br. J. Cancer"},{"issue":"4\u20136","key":"156_CR16","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1159\/000086993","volume":"68","author":"A Magnino","year":"2005","unstructured":"Magnino, A., Gatti, M., Massucco, P., et al.: Phase II trial of primary radiation therapy and concurrent chemotherapy for patients with locally advanced pancreatic cancer. Oncology 68(4\u20136), 493\u2013499 (2005)","journal-title":"Oncology"},{"issue":"1\u20132","key":"156_CR17","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1159\/000090030","volume":"6","author":"N Oya","year":"2006","unstructured":"Oya, N., Shibuya, K., Sakamoto, T., et al.: Chemoradiotherapy in patients with pancreatic carcinoma: phase-I study with a fixed radiation dose and escalating doses of weekly gemcitabine. Pancreatology 6(1\u20132), 109\u2013116 (2006)","journal-title":"Pancreatology"},{"issue":"4","key":"156_CR18","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1016\/j.ijrobp.2006.10.015","volume":"67","author":"A Brade","year":"2007","unstructured":"Brade, A., Brierley, J., Oza, A., et al.: Concurrent gemcitabine and radiotherapy with and without neoadjuvant gemcitabine for locally advanced unresectable or resected pancreatic cancer: a phase I-II study. Int. J. Radiat. Oncol. Biol. Phys. 67(4), 1027\u20131036 (2007)","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"34","key":"156_CR19","doi-asserted-by":"publisher","first-page":"5311","DOI":"10.3748\/wjg.14.5311","volume":"14","author":"H Igarashi","year":"2008","unstructured":"Igarashi, H., Ito, T., Kawabe, K., et al.: Chemoradiotherapy with twice-weekly administration of low-dose gemcitabine for locally advanced pancreatic cancer. World J. Gastroenterol. 14(34), 5311\u20135315 (2008)","journal-title":"World J. Gastroenterol."},{"issue":"4C","key":"156_CR20","first-page":"2369","volume":"28","author":"K Maemura","year":"2008","unstructured":"Maemura, K., Shinchi, H., Noma, H., et al.: Comparison of hyper-fractionated accelerated and standard fractionated radiotherapy with concomitant low-dose gemcitabine for unresectable pancreatic cancer. Anticancer Res. 28(4C), 2369\u20132372 (2008)","journal-title":"Anticancer Res."},{"issue":"5","key":"156_CR21","doi-asserted-by":"publisher","first-page":"1426","DOI":"10.1016\/j.ijrobp.2009.06.053","volume":"77","author":"N Girard","year":"2010","unstructured":"Girard, N., Mornex, F., Bossard, N., et al.: Estimating optimal dose of twice-weekly gemcitabine for concurrent chemoradiotherapy in unresectable pancreatic carcinoma: mature results of GEMRT-01 Phase I trial. Int. J. Radiat. Oncol. Biol. Phys. 77(5), 1426\u20131432 (2010)","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"31","key":"156_CR22","doi-asserted-by":"publisher","first-page":"4105","DOI":"10.1200\/JCO.2011.34.8904","volume":"29","author":"PJ Loehrer Sr","year":"2011","unstructured":"Loehrer Sr., P.J., Feng, Y., Cardenes, H., et al.: Gemcitabine alone versus gemcitabine plus radiotherapy in patients with locally advanced pancreatic cancer: an eastern cooperative oncology group trial. J. Clin. Oncol. 29(31), 4105\u20134112 (2011)","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"156_CR23","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1097\/COC.0b013e3181c4c7a8","volume":"34","author":"K Shibuya","year":"2011","unstructured":"Shibuya, K., Oya, N., Fujii, T., et al.: Phase II study of radiation therapy combined with weekly low-dose gemcitabine for locally advanced, unresectable pancreatic cancer. Am. J. Clin. Oncol. 34(2), 115\u2013119 (2011)","journal-title":"Am. J. Clin. Oncol."},{"issue":"5","key":"156_CR24","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1097\/COC.0b013e3181e9c103","volume":"34","author":"HR Cardenes","year":"2011","unstructured":"Cardenes, H.R., Moore, A.M., Johnson, C.S., et al.: A phase II study of gemcitabine in combination with radiation therapy in patients with localized, unresectable, pancreatic cancer: a Hoosier Oncology Group study. Am. J. Clin. Oncol. 34(5), 460\u2013465 (2011)","journal-title":"Am. J. Clin. Oncol."},{"issue":"3","key":"156_CR25","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1016\/j.ijrobp.2009.02.013","volume":"76","author":"GC Mattiucci","year":"2010","unstructured":"Mattiucci, G.C., Morganti, A.G., Valentini, V., et al.: External beam radiotherapy plus 24-hour continuous infusion of gemcitabine in unresectable pancreatic carcinoma: long-term results of a phase II study. Int. J. Radiat. Oncol. Biol. Phys. 76(3), 831\u2013838 (2010)","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"6","key":"156_CR26","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1200\/JCO.2007.13.9014","volume":"26","author":"W Small Jr","year":"2008","unstructured":"Small Jr., W., Berlin, J., Freedman, G.M., et al.: Full-dose gemcitabine with concurrent radiation therapy in patients with nonmetastatic pancreatic cancer: a multicenter phase II trial. J. Clin. Oncol. 26(6), 942\u2013947 (2008)","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"156_CR27","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.ijrobp.2008.04.012","volume":"73","author":"PI Huang","year":"2009","unstructured":"Huang, P.I., Chao, Y., Li, C.P., et al.: Efficacy and factors affecting outcome of gemcitabine concurrent chemoradiotherapy in patients with locally advanced pancreatic cancer. Int. J. Radiat. Oncol. Biol. Phys. 73(1), 159\u2013165 (2009)","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"4","key":"156_CR28","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1159\/000151226","volume":"54","author":"M Tada","year":"2008","unstructured":"Tada, M., Arizumi, T., Nakai, Y., et al.: Efficacy of gemcitabine for locally advanced pancreatic cancer: comparison with 5-fluorouracil-based chemoradiotherapy. Chemotherapy 54(4), 302\u2013308 (2008)","journal-title":"Chemotherapy"},{"issue":"10","key":"156_CR29","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1002\/jhbp.130","volume":"21","author":"H Yanagimoto","year":"2014","unstructured":"Yanagimoto, H., Ishii, H., Nakai, Y., et al.: Improved survival with combined gemcitabine and S-1 for locally advanced pancreatic cancer: pooled analysis of three randomized studies. J. Hepatobiliary Pancreat. Sci. 21(10), 761\u2013766 (2014)","journal-title":"J. Hepatobiliary Pancreat. Sci."},{"issue":"15","key":"156_CR30","doi-asserted-by":"publisher","first-page":"3509","DOI":"10.1200\/JCO.2005.06.023","volume":"23","author":"C Louvet","year":"2005","unstructured":"Louvet, C., Labianca, R., Hammel, P., et al.: Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial. J. Clin. Oncol. 23(15), 3509\u20133516 (2005)","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"156_CR31","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1093\/annonc\/mdw607","volume":"28","author":"TRJ Evans","year":"2017","unstructured":"Evans, T.R.J., Van Cutsem, E., Moore, M.J., et al.: Phase 2 placebo-controlled, double-blind trial of dasatinib added to gemcitabine for patients with locally-advanced pancreatic cancer. Ann. Oncol. 28(2), 354\u2013361 (2017)","journal-title":"Ann. Oncol."},{"issue":"2","key":"156_CR32","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1007\/BF02698046","volume":"24","author":"M Cengiz","year":"2007","unstructured":"Cengiz, M., Zorlu, F., Yalcin, S., et al.: Concurrent gemcitabine and radiotherapy for locally advanced pancreatic cancer. Med. Oncol. 24(2), 239\u2013243 (2007)","journal-title":"Med. Oncol."},{"issue":"2","key":"156_CR33","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1016\/j.ijrobp.2011.07.013","volume":"83","author":"K Ogawa","year":"2012","unstructured":"Ogawa, K., Ito, Y., Hirokawa, N., et al.: Concurrent radiotherapy and gemcitabine for unresectable pancreatic adenocarcinoma: impact of adjuvant chemotherapy on survival. Int. J. Radiat. Oncol. Biol. Phys. 83(2), 559\u2013565 (2012)","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"10","key":"156_CR34","doi-asserted-by":"publisher","first-page":"2207","DOI":"10.1002\/1097-0142(19900515)65:10<2207::AID-CNCR2820651007>3.0.CO;2-Y","volume":"65","author":"S Cullinan","year":"1990","unstructured":"Cullinan, S., Moertel, C.G., Wieand, H.S., et al.: A phase III trial on the therapy of advanced pancreatic carcinoma. Evaluations of the Mallinson regimen and combined 5-fluorouracil, doxorubicin, and cisplatin. Cancer 65(10), 2207\u20132212 (1990)","journal-title":"Cancer"},{"issue":"2","key":"156_CR35","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.radonc.2011.05.038","volume":"99","author":"J Huang","year":"2011","unstructured":"Huang, J., Robertson, J.M., Margolis, J., et al.: Long-term results of full-dose gemcitabine with radiation therapy compared to 5-fluorouracil with radiation therapy for locally advanced pancreas cancer. Radiother. Oncol. 99(2), 114\u2013119 (2011)","journal-title":"Radiother. Oncol."},{"issue":"2","key":"156_CR36","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.radonc.2011.04.001","volume":"99","author":"CP Zhu","year":"2011","unstructured":"Zhu, C.P., Shi, J., Chen, Y.X., et al.: Gemcitabine in the chemoradiotherapy for locally advanced pancreatic cancer: a meta-analysis. Radiother. Oncol. 99(2), 108\u2013113 (2011)","journal-title":"Radiother. Oncol."},{"issue":"1","key":"156_CR37","doi-asserted-by":"publisher","first-page":"477","DOI":"10.3892\/mmr.2015.4500","volume":"19","author":"J Chen","year":"2019","unstructured":"Chen, J., Chen, L., Yu, J., et al.: Meta-analysis of current chemotherapy regimens in advanced pancreatic cancer to prolong survival and reduce treatment-associated toxicities. Mol. Med. Rep. 19(1), 477\u2013489 (2019)","journal-title":"Mol. Med. Rep."},{"key":"156_CR38","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1186\/1748-717X-8-148","volume":"8","author":"A Tozzi","year":"2013","unstructured":"Tozzi, A., Comito, T., Alongi, F., et al.: SBRT in unresectable advanced pancreatic cancer: preliminary results of a mono-institutional experience. Radiat. Oncol. 8, 148 (2013)","journal-title":"Radiat. Oncol."},{"key":"156_CR39","unstructured":"World Health Organisation. WHO handbook for reporting results of cancer treatment. Offset Pub. 48. World Health Organisation, Geneva (1979)"},{"issue":"3","key":"156_CR40","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","volume":"92","author":"Patrick Therasse","year":"2000","unstructured":"Therasse, P., Arbuck, S.G., Eisenhauer, E.A., et al.: New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J. Natl. Cancer Inst. 92, 205\u2013216 (200)","journal-title":"JNCI: Journal of the National Cancer Institute"},{"key":"156_CR41","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/1748-717X-5-57","volume":"5","author":"BC Ferreira","year":"2010","unstructured":"Ferreira, B.C., Lopes, M.C., Mateus, J., et al.: Radiobiological evaluation of forward and inverse IMRT using different fractionations for head and neck tumours. Radiat. Oncol. 5, 57 (2010)","journal-title":"Radiat. Oncol."},{"issue":"1","key":"156_CR42","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.prro.2013.01.005","volume":"4","author":"IC Moraru","year":"2014","unstructured":"Moraru, I.C., Tai, A., Erickson, B., Li, X.A.: Radiation dose responses for chemoradiation therapy of pancreatic cancer: an analysis of compiled clinical data using biophysical models. Pract. Radiat. Oncol. 4(1), 13\u201319 (2014)","journal-title":"Pract. Radiat. Oncol."},{"key":"156_CR43","doi-asserted-by":"publisher","first-page":"145","DOI":"10.3389\/fonc.2015.00145","volume":"5","author":"M Durante","year":"2015","unstructured":"Durante, M., Tommasino, F., Yamada, S.: Modeling combined chemotherapy and particle therapy for locally advanced pancreatic cancer. Front. Oncol. 5, 145 (2015)","journal-title":"Front. Oncol."},{"issue":"1","key":"156_CR44","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1093\/jrr\/rrt111","volume":"55","author":"JD Chapman","year":"2014","unstructured":"Chapman, J.D.: Can the two mechanisms of tumor cell killing by radiation be exploited for therapeutic gain? J. Radiat. Res. 55(1), 2\u20139 (2014)","journal-title":"J. Radiat. Res."},{"key":"156_CR45","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.critrevonc.2016.05.003","volume":"103","author":"B Bari De","year":"2016","unstructured":"De Bari, B., Porta, L., Mazzola, R., et al.: Hypofractionated radiotherapy in pancreatic cancer: lessons from the past in the era of stereotactic body radiation therapy. Crit. Rev. Oncol. Hematol. 103, 49\u201361 (2016)","journal-title":"Crit. Rev. Oncol. Hematol."}],"container-title":["IFMBE Proceedings","XV Mediterranean Conference on Medical and Biological Engineering and Computing \u2013 MEDICON 2019"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/978-3-030-31635-8_156","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,29]],"date-time":"2022-09-29T19:31:45Z","timestamp":1664479905000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/978-3-030-31635-8_156"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,25]]},"ISBN":["9783030316341","9783030316358"],"references-count":45,"URL":"https:\/\/doi.org\/10.1007\/978-3-030-31635-8_156","relation":{},"ISSN":["1680-0737","1433-9277"],"issn-type":[{"type":"print","value":"1680-0737"},{"type":"electronic","value":"1433-9277"}],"subject":[],"published":{"date-parts":[[2019,9,25]]},"assertion":[{"value":"25 September 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}},{"value":"None.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"MEDICON","order":1,"name":"conference_acronym","label":"Conference Acronym","group":{"name":"ConferenceInfo","label":"Conference Information"}},{"value":"Mediterranean Conference on Medical and Biological Engineering and Computing","order":2,"name":"conference_name","label":"Conference Name","group":{"name":"ConferenceInfo","label":"Conference Information"}},{"value":"Coimbra","order":3,"name":"conference_city","label":"Conference City","group":{"name":"ConferenceInfo","label":"Conference Information"}},{"value":"Portugal","order":4,"name":"conference_country","label":"Conference Country","group":{"name":"ConferenceInfo","label":"Conference Information"}},{"value":"2019","order":5,"name":"conference_year","label":"Conference Year","group":{"name":"ConferenceInfo","label":"Conference Information"}},{"value":"26 September 2019","order":7,"name":"conference_start_date","label":"Conference Start Date","group":{"name":"ConferenceInfo","label":"Conference Information"}},{"value":"28 September 2019","order":8,"name":"conference_end_date","label":"Conference End Date","group":{"name":"ConferenceInfo","label":"Conference Information"}},{"value":"medicon2019a","order":10,"name":"conference_id","label":"Conference ID","group":{"name":"ConferenceInfo","label":"Conference Information"}},{"value":"http:\/\/www.medicon2019.org","order":11,"name":"conference_url","label":"Conference URL","group":{"name":"ConferenceInfo","label":"Conference Information"}}]}}